GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Arcadia Biosciences Inc (NAS:RKDA) » Definitions » Piotroski F-Score

Arcadia Biosciences (Arcadia Biosciences) Piotroski F-Score : 2 (As of May. 07, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Arcadia Biosciences Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Arcadia Biosciences has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Arcadia Biosciences's Piotroski F-Score or its related term are showing as below:

RKDA' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 5
Current: 2

During the past 12 years, the highest Piotroski F-Score of Arcadia Biosciences was 5. The lowest was 1. And the median was 4.


Arcadia Biosciences Piotroski F-Score Historical Data

The historical data trend for Arcadia Biosciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcadia Biosciences Piotroski F-Score Chart

Arcadia Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 4.00 2.00 4.00 2.00

Arcadia Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 3.00 3.00 2.00

Competitive Comparison of Arcadia Biosciences's Piotroski F-Score

For the Packaged Foods subindustry, Arcadia Biosciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcadia Biosciences's Piotroski F-Score Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Arcadia Biosciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Arcadia Biosciences's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -9.384 + 0.823 + -2.567 + -2.853 = $-13.98 Mil.
Cash Flow from Operations was -3.466 + -4.798 + -2.885 + -4.145 = $-15.29 Mil.
Revenue was 1.509 + 1.389 + 1.597 + 1.17 = $5.67 Mil.
Gross Profit was 0.684 + 0.408 + 0.495 + 0.5 = $2.09 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(28.922 + 30.41 + 26.798 + 23.466 + 19.705) / 5 = $25.8602 Mil.
Total Assets at the begining of this year (Dec22) was $28.92 Mil.
Long-Term Debt & Capital Lease Obligation was $0.16 Mil.
Total Current Assets was $14.97 Mil.
Total Current Liabilities was $3.59 Mil.
Net Income was -4.488 + -3.777 + -2.867 + -4.244 = $-15.38 Mil.

Revenue was 3.22 + 3.858 + 1.57 + 0.744 = $9.39 Mil.
Gross Profit was -0.238 + 0.411 + 0.442 + -0.156 = $0.46 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(43.918 + 38.799 + 35.008 + 34.474 + 28.922) / 5 = $36.2242 Mil.
Total Assets at the begining of last year (Dec21) was $43.92 Mil.
Long-Term Debt & Capital Lease Obligation was $1.01 Mil.
Total Current Assets was $25.40 Mil.
Total Current Liabilities was $4.21 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Arcadia Biosciences's current Net Income (TTM) was -13.98. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Arcadia Biosciences's current Cash Flow from Operations (TTM) was -15.29. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-13.981/28.922
=-0.48340364

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-15.376/43.918
=-0.35010702

Arcadia Biosciences's return on assets of this year was -0.48340364. Arcadia Biosciences's return on assets of last year was -0.35010702. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Arcadia Biosciences's current Net Income (TTM) was -13.98. Arcadia Biosciences's current Cash Flow from Operations (TTM) was -15.29. ==> -15.29 <= -13.98 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0.155/25.8602
=0.00599377

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=1.007/36.2242
=0.0277991

Arcadia Biosciences's gearing of this year was 0.00599377. Arcadia Biosciences's gearing of last year was 0.0277991. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=14.972/3.59
=4.17047354

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=25.398/4.209
=6.0342124

Arcadia Biosciences's current ratio of this year was 4.17047354. Arcadia Biosciences's current ratio of last year was 6.0342124. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Arcadia Biosciences's number of shares in issue this year was 1.362. Arcadia Biosciences's number of shares in issue last year was 0.674. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2.087/5.665
=0.36840247

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.459/9.392
=0.04887138

Arcadia Biosciences's gross margin of this year was 0.36840247. Arcadia Biosciences's gross margin of last year was 0.04887138. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=5.665/28.922
=0.19587165

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=9.392/43.918
=0.21385309

Arcadia Biosciences's asset turnover of this year was 0.19587165. Arcadia Biosciences's asset turnover of last year was 0.21385309. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+1+0+0+1+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Arcadia Biosciences has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Arcadia Biosciences  (NAS:RKDA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Arcadia Biosciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Arcadia Biosciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcadia Biosciences (Arcadia Biosciences) Business Description

Traded in Other Exchanges
Address
5950 Sherry Lane, Suite 215, Dallas, TX, USA, 75225
Arcadia Biosciences Inc is a producer and marketer of innovative, plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements primarily in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water, ProVault topical pain relief, and SoulSpring bath and body care.
Executives
Thomas J. Schaefer officer: Chief Financial Officer 202 COUSTEAU PLACE STE 105, DAVIS CA 95618
Stanley Jr Jacot officer: Chief Executive Officer 202 COUSTEAU PLACE STE 105, DAVIS CA 95618
Pamela Haley officer: Chief Financial Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Laura Pitlik officer: Chief Marketing Officer 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Chris Cuvelier officer: Chief Growth Officer 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Deborah D Carosella director 3603 HAVEN AVE, SUITE E, MENLO PARK CA 94025
Matthew T Plavan officer: Chief Financial Officer C/O THERMOGENESIS CORP., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Randall Shultz officer: Chief Technology Officer 4222 E. THOMAS ROAD, SUITE 320, PHOEBIIX AZ 85018
Sarah Reiter officer: Chief Commercial Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Lilian Shackelford Murray director 228 BEACH ROAD, BELVEDERE CA 94920
Kevin Comcowich director C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
Eric J. Rey director, officer: President and CEO ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Zhongjin Lu officer: VP Product Development ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Amy Yoder director C/O SPECTRUM BRANDS, INC., 6 CONCOURSE PARKWAY, SUITE 3300, ATLANTA GA 30328